FDA Approves Obizur for Treatment of Acquired Hemophilia A
The US Food and Drug Administration approved the use of Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency. See full story at fda.gov.
NSAIDs Linked to Increased Venous Thromboembolism Risk
Nonsteroidal anti-inflammatory drugs (NSAIDs) may almost double the risk
for venous thromboembolism (VTE), including deep venous thrombosis and
pulmonary embolism, according to an article published online September 24 in Rheumatology. See full story at Medscape.com (free registration may be required)
World Thrombosis Day is October 13
October 13, 2014 is the first ever World Thrombosis Day, marking a day to promote education and awareness about thrombosis and venous thromboembolism (VTE). Find out more about why they chose October 13th
and find resources and videos to learn and share at www.worldthrombosisday.org
Plant-Based Delivery Platform Improves Hemophilia Treatment & Addresses Inhibitors
Researchers at Penn's School of Dental Medicine have developed a method of delivery for factor VIII that promotes tolerance and prevents inhibitor formation. The method also appears to reverse formation of inhibitors over time in testing of mice.
Hemophilia B Treatment Regimen Meets Endpoint in Phase 3 Trial
Pfizer Inc. announced positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe hemophilia B.
See full story at biospace.com
NHF and McMaster University Collaborate on Guidelines for Hemophilia Care Models
The National Hemophilia Foundation is undertaking a project to develop evidence-based clinical practice guidelines in hemophilia. The NHF will focus on evaluating different care models, including the comprehensive care model of the Hemophilia Treatment Centers with a goal to support patient-centered decision making and optimize hemophilia care for each patient. See full story at hemophilia.org
Listen to Dr. Tim Bernard Discuss Pediatric Stroke with CPR's Colorado Matters
Our own Dr. Tim Bernard had the opportunity to discuss pediatric stroke with the popular radio show "Colorado Matters" on Colorado Public Radio. He and the father of one of our patients talk about pediatric stroke, how it affects families and what the HTC research team is doing to discover more. You can listen to the entire interview at cpr.org. (photo: CU School of Medicine)
FDA Approves Longer-Lasting Drug Eloctate For Treatment of Hemophilia A
The Food and Drug Administration has approved Eloctate, a new long-acting drug by Biogen Idec Inc., for the treatment of hemophilia A. The approval comes just two months after the FDA approved Biogen Idec's hemophilia B treatment Alprolix. Full Story at bostonglobe.com
European Commission Approves Pradaxa for Prevention of DVT and PE
Boehringer Ingelheim announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). The U.S. FDA approved Pradaxa earlier this year. Full Story at news-medical.net
Drug Companies Pledge Factor VIII Donation in Developing Countries
Biogen Idec Inc. and their partner Swedish Orphan Biovitrum AB recently announced that they will donate one billion international units of Factor VIII therapy for humanitarian aid programs. Full Story at healio.com and informational video can be found at wn.com.
Dr. Tim Bernard in Denver Post Article-CU Grant & Research on Pediatric Stroke
The HTC's Dr. Tim Bernard was featured in a recent article in the Denver Post that highlighted the $2.5 million grant that will fund research that is now underway on the effects of strokes on children. Dr. Bernard is one of the experts on the research team studying pediatric stroke. Full Story at denverpost.com (photo: Kathryn Scott Osler, The Denver Post)
The HTC Has Also Joined Twitter! Follow Us and Get Involved!
The HTC has joined Twitter and created a profile here: https://twitter.com/HTCColorado
. Any of our patients, families, fellow providers and other interested parties are welcome to follow us and keep up with the latest news, events and information about our center and the disorders we treat.
See our Social Media page for more.
The HTC Has Joined Facebook. Like Our Page and Connect With Us Today!
The HTC has joined Facebook by creating a page here: https://www.facebook.com/ColoradoHTC If Facebook is a social media tool our patients and families use, we hope they will connect with us and keep up with the latest news, events and information about our center, hemophilia, bleeding and clotting disorders and pediatric stroke. See our Social Media page here.